HDAC2 Immunoprecipitation (IP) and Activity Assay Kit

Total Page:16

File Type:pdf, Size:1020Kb

HDAC2 Immunoprecipitation (IP) and Activity Assay Kit HDAC2 Immunoprecipitation (IP) and Activity Assay Kit Catalog Number EPI012 Storage Temperature –20 °C TECHNICAL BULLETIN Product Description AFC Standard (1 mM) (Yellow Cap) 100 mL Histone deacetylases (HDACs) play a central role in Catalog Number EPI012E controlling cell cycle regulation, cell differentiation, and tissue development. These proteins have crucial roles Rabbit HDAC2 Antibody (Red Cap) 250 mL in development and physiology, especially in the heart Catalog Number EPI012F and nervous system. They are also deeply involved in cellular proliferation, cell cycle, and apoptosis. Rabbit IgG (Control Antibody) (Green Cap) 100 mL Catalog Number EPI012G The HDAC2 Immunoprecipitation (IP) and Activity Assay Kit provides an antibody-based method to Protein-A/G SepharoseÒ Beads (Blue Cap) 650 mL specifically immunoprecipitate the HDAC2 complex Catalog Number EPI012H from cells and tissues, and to measure HDAC2 activity fluorometrically. HDAC2 is immunoprecipitated from Positive Control (Jurkat Cell Lysate) (Violet Cap) 1 vl cell, nuclear, or tissue extract(s) using HDAC2 antibody Catalog Number EPI012I followed by capturing the complex on protein-A/G beads. The immunoprecipitated complex is incubated Reagents and equipment required but not provided. with the HDAC substrate. Only the deacetylated · 96 well black plates for fluorometric assays. substrate is cleaved by the Developer to produce a · Fluorescence plate reader fluorophore, which can be easily analyzed using a · Rotary mixer fluorescence plate reader. The kit is suitable for · Phosphate Buffered Saline (Catalog Number measurement of HDAC2 activity of immunoprecipitated P5368 or equivalent) complex or purified enzyme from human, mouse, or rat · Protease Inhibitor Cocktail (Catalog Number P8340 samples. or equivalent) Components · CelLyticä NuCLEARä Extraction Kit (Catalog The kit is sufficient for 25 assays in 96 well plates. Number NXTRACT or equivalent) HDAC Assay Buffer (Wide Mouth Bottle) 9 mL Precautions and Disclaimer Catalog Number EPI012A This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Cell Lysis Buffer (Narrow Mouth Bottle) 100 mL Data Sheet for information regarding hazards and safe Catalog Number EPI012B handling practices. Storage/Stability HDAC Substrate (Amber Cap) 100 mL Catalog Number EPI012C The kit is shipped on wet ice. Store the kit at –20 °C, protected from light. However, some components have different storage temperatures once reconstituted. See Developer (Orange Cap) 500 mL Preparation Instructions for storage conditions of Catalog Number EPI012D individual components. 2 Preparation Instructions Procedure Briefly centrifuge vials before opening. Use ultrapure Sample Preparation water for the preparation of reagents. To maintain 1. Cell Lysate reagent integrity, avoid repeated freeze/thaw cycles. a. Grow cells in 6 or 12 well plates, treat as Read the entire protocol before performing the assay. desired. b. For adherent cells, remove medium and wash HDAC Assay Buffer – Store at –20 °C or 2–8 °C. Briefly cells with PBS. warm to 37 °C before use. c. For suspension cells, collect cells by centrifugation, wash cells with PBS at room Cell Lysis Buffer – Thaw Cell Lysis Buffer and add temperature, and collect cells again by protease inhibitors as per manufacturer’s centrifugation. instructions. Make fresh as needed and keep on ice d. Remove the PBS, place the plate on ice, and while in use. add cold Lysis Buffer containing protease inhibitors. Add 125 mL/well (12 well plate) or HDAC Substrate – Store at –20 °C. 250 mL/well (6 well plate). e. Keep on ice for one minute. Developer – Aliquot 250 mL into tubes and store at f. Scrape the cells and gently transfer the –20 °C. Keep on ice while in use. Use within disrupted cell suspension into a cooled 2 months. microcentrifuge tube. g. Mix on a rotary mixer at 2–8 °C for 30 minutes. AFC (7-amino-4-trifluoromethyl coumarin) Standard – h. Centrifuge at 10,000 ´ g for 10 minutes at Store at –20 °C. 2–8 °C, then discard cell debris pellet. Protein-A/G Sepharose Beads (50% slurry in 20% 2. Nuclear Extract ethanol aqueous solution) – Store at 2–8 °C after Prepare nuclear extracts from 2 ´ 105 to 2 ´ 106 thawing. Do not freeze. cells using CelLytic NuCLEAR Extraction Kit (Catalog Number NXTRACT) or other equivalent method. Positive Control – Reconstitute with 25 mL of water. Mix gently by pipetting. Aliquot and store at –70 °C. Use 3. Tissue Extract within 2 months. a. Snap freeze dissected tissue and immediately grind to a fine powder using a mortar and Phosphate Buffered Saline (PBS) – Chill PBS before pestle in a liquid nitrogen bath. use. Add protease inhibitors as per manufacturer’s b. Transfer the ground tissue to a pre-weighed instructions. Make fresh as needed and keep on ice chilled tube. while in use. c. Weigh the powder and add 300 mL of Lysis Buffer containing protease inhibitors per 5 mg of tissue. d. Mix on a rocker at 2–8 °C for about an hour. e. Pass the lysate 3 times through a 25 gauge needle. f. Collect the lysate and centrifuge at high speed at 2–8 °C for 5 minutes to remove debris. g. Transfer the supernatant to a fresh tube. Note: Repeated freeze-thaw of sample will cause loss in HDAC activity. 4. Protein Estimation Determine the protein concentration using the Bradford Assay. 3 Immunoprecipitation HDAC Activity Assay 1. Antibody Binding 1. Warm HDAC Assay Buffer to 37 °C prior to use. a. Cell lysates, Nuclear and Tissue extracts Mix enough reagents for the number of assays to (CL/NE/TE) are in the linear range for HDAC be performed including sample and background activity when 50–100 mg protein is used. If control. For each assay, prepare 168 mL of the samples have high HDAC levels, the amount Reaction Mix according to the scheme in Table 1. used needs to be standardized. b. For each IP reaction (sample or control), add Table 1. 50–100 mg CL/NE/TE to a chilled tube on ice. Reaction Mix c. Add 10 mL of HDAC1 Antibody to samples. Add 10 mL of Control Antibody to samples to Reagent Volume prepare background controls. HDAC Assay Buffer 164 mL d. Bring the volume to 500 mL with PBS containing HDAC Substrate 4 mL protease inhibitor. Total volume 168 mL e. Incubate overnight at 2–8 °C on a rotary mixer. 2. Add 168 mL of Reaction Mix to each sample and 2. Preparation of Protein-A/G Beads: background control tube, mix gently, and incubate a. Use wide bore pipette tips when pipetting at 37 °C for two hours. beads. b. Wash the protein-A/G beads (25 mL of 50% 3. The Positive Control is used to measure total slurry per reaction) 2 times with 1 mL of PBS, by centrifuging at 14,000 ´ g for 10 seconds HDAC Activity. In a separate tube add 2–5 mL of and aspirating the supernatant between Positive Control, 4 mL HDAC Substrate, and adjust washes. the volume to 180 mL with HDAC Assay Buffer. Mix c. Suspend as 50% slurry in PBS. gently and incubate at 37 °C for two hours. 3. Bead Capture: 4. Add 20 mL of the Developer to each tube and mix. a. After overnight incubation of the sample/ Incubate for 30 minutes at 37 °C. antibody mixture (step 1e), add 25 mL of the protein-A/G bead slurry (step 2c) to each tube 5. Preparation of AFC Standards for Standard Curve– and incubate for an hour at 2–8 °C. Dilute the 1 mM AFC Standard to 10 mM by adding b. Collect the beads by centrifugation at 14,000 ´ g for 10 seconds at 2–8 °C. 10 mL of 1 mM AFC Standard to 990 mL of water. c. Wash beads 3 times with 1 mL of PBS, by Add 0, 20, 40, 60, 80, and 100 mL of diluted 10 mM centrifuging at 14,000 ´ g for 10 seconds and AFC Standard into individual wells in a 96 well aspirating the supernatant between washes. black plate. Adjust the volume to 100 mL/well with d. Assay HDAC Activity immediately. HDAC Assay buffer to generate 0, 200, 400, 600, 800, and 1,000 pmole/well of AFC Standard, respectively. Mix well. 6. Centrifuge the Positive Control, Background Control, and Sample tubes at 14,000 ´ g for 2 minutes at room temperature. 7. Transfer 100 mL of each reaction supernatant to individual wells in a black plate. 8. Read fluorescence at (lex = 380/lem = 500 nm). 4 Results HDAC Activity Calculations Subtract the Background Control reading from all Plot the AFC Standard Curve from the fluorescence Sample readings. Apply the corrected sample reading measurements of the AFC Standards. to the AFC Standard Curve to obtain B (pmole of AFC Note: A new standard curve must be set up each time in the sample wells). the assay is run. HDAC Activity = 2 ´ B/TS = pmole/min/mg = milliunits Figure 1. AFC Standard Curve. where: B = AFC amount from the Standard Curve (pmole) 2 = Sample dilution factor* T = Reaction time (120 minutes) S = Sample amount (mg) * Reaction Volume (Sample and Background Control) = 200 mL = ~12 mL beads + 168 mL reaction mix + 20 mL Developer. 100 mL of the reaction is used to measure the fluorescence and hence the sample dilution factor is 2. Unit definition: One unit of HDAC is the amount of enzyme that generates one nanomole of deacetylated substrate/min/mg at 37 °C. Figure 2. HDAC2 IP Activity Assay of HeLa cell lysate and Nuclear Extract and HDAC Activity Assay of Positive Control. Assays were performed according to the kit protocol. CelLytic and NuCLEAR are trademarks of Sigma- Aldrich Co. LLC. Sepharose is a registered trademark of GE Healthcare.
Recommended publications
  • Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development
    Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development Gerlie Gieser, Ph.D. Office of Clinical Pharmacology, Div. IV Objectives • Outline the Phase 1 studies conducted to characterize the Clinical Pharmacology of a drug; describe important design elements of and the information gained from these studies. • List the Clinical Pharmacology characteristics of an Ideal Drug • Describe how the Clinical Pharmacology information from Phase 1 can help design Phase 2/3 trials • Discuss the timing of Clinical Pharmacology studies during drug development, and provide examples of how the information generated could impact the overall clinical development plan and product labeling. Phase 1 of Drug Development CLINICAL DEVELOPMENT RESEARCH PRE POST AND CLINICAL APPROVAL 1 DISCOVERY DEVELOPMENT 2 3 PHASE e e e s s s a a a h h h P P P Clinical Pharmacology Studies Initial IND (first in human) NDA/BLA SUBMISSION Phase 1 – studies designed mainly to investigate the safety/tolerability (if possible, identify MTD), pharmacokinetics and pharmacodynamics of an investigational drug in humans Clinical Pharmacology • Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the drug in humans – PK: what the body does to the drug (Absorption, Distribution, Metabolism, Excretion) – PD: what the drug does to the body • PK and PD profiles of the drug are influenced by physicochemical properties of the drug, product/formulation, administration route, patient’s intrinsic and extrinsic factors (e.g., organ dysfunction, diseases, concomitant medications,
    [Show full text]
  • Challenges Associated with the Development and Validation of Flow Cytometry Assays
    Challenges associated with the development and validation of flow cytometry assays Carolyne Dumont, Eliane Moisan, Martin Poirier, Marie-Hélène Côté, and Marie-Soleil Piché 1 INTRODUCTION 2 Case Study 1 3 Case Study 2 Development of a PD marker by flow cytometry to assess the efficacy of Development of a flow cytometry assay for the measurement of basophil Flow cytometry is a technology allowing multi-parametric analysis of thousands of particles per second and helps to a chemokine neutralizing antibody activation in the context of a Phase III clinical study adequately identify or functionally characterize complex cell populations of interest. It is often used in basic research, Assay Design: The assay was required for the evaluation of pharmacodynamics (inhibition an agonist’s granulocytes activation activity) in Assay Design: Human whole blood samples were spiked with the different controls (or compounds in the clinical study) and further discovery, preclinical and clinical trials. With the increasing proportion of biologics in the pipeline, flow cytometry has proven preclinical studies. Non-Human Primate (NHP) or rat blood from treated animals was incubated at 3 conditions and granulocyte activation stained with an anti-CCR3 and anti-CD63 antibody. The validations stimulation conditions tested included a negative control (PBS) and itself to be an indispensable tool to assess safety, receptor occupancy (RO) or pharmacodynamics (PD). was measured as CD11b expression by flow cytometry (MFI). The conditions tested included a negative control (PBS), a positive control two positive controls (anti-FcεRI and fMLP). Basophils were identified as CCR3+ and upon activation, CD63 became externalized and (fMLP) and the test condition (agonist).
    [Show full text]
  • Simple, Rapid Ligand-Binding Assay Using Immobilized Cellular Membranes
    Simple, Rapid Ligand-Binding Assay Using Immobilized Cellular Membranes Paula Denney Eason, Renée C. Benson, Jenny T. Ly, Rachel A. Saxer, James L. Wilbur, George B. Sigal, Eli N. Glezer, Hans A. Biebuyck, Jacob N. Wohlstadter, and Robert M. Umek TM TM A division of Meso Scale Diagnostics,TM LLC. Simple, Rapid Ligand-Binding Assay Using Immobilized Cellular Membranes Abstract This poster presents a robust, receptor-ligand binding assay based upon a novel assay platform developed by Meso Scale DiscoveryTM (MSDTM). MSD’s platform combines array technologies and electrochemiluminescence detection to achieve ultra-fast, highly sensitive assays in a homogeneous format. Cellular membranes containing the EGF receptor were passively adsorbed to MSD proprietary coated electrodes embedded in multi-well plates. Binding of EGF to the EGF receptor was detected by inducing and measuring electrochemi- luminescence from a labeled EGF ligand. Approximately 1000 cell equivalents per well yielded a signal to background ratio of 20. The observed KD agrees with that reported in the literature and demonstrates that immobilization of the membranes and modification of the ligand do not alter the binding affinity. Binding specificity was confirmed with two inhibitors. The assay can be readily adapted to facilitate analysis of a broad array of receptor-ligand interactions. TM TM A division of Meso Scale Diagnostics,TM LLC. Simple, Rapid Ligand-Binding Assay Using Immobilized Cellular Membranes TM Multi-Array TechnologyTM Multi-Array Technology Unified technology platform with instruments, plates and reagents for drug discovery for drug discovery. Combines the power of microarrays with the sensitivity of electrochemiluminescence Combines the power of microarrays with the sensitivity of electrochemiluminescence.96-, 384- and 1536 microplate formats 96-,Multi-Spot 384- TMand plates 1536 with microplate high density formats.
    [Show full text]
  • UBI® SARS-Cov-2 ELISA INSTRUCTIONS for USE
    UBI® SARS-CoV-2 ELISA INSTRUCTIONS FOR USE FOR IN VITRO DIAGNOSTIC USE ONLY FOR EMERGENCY USE AUTHORIZATION ONLY FOR PRESCRIPTION USE ONLY INTENDED USE The UBI® SARS-CoV-2 ELISA is an Enzyme-Linked Immunosorbent Assay (ELISA) intended for qualitative detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (sodium heparin or dipotassium (K2) EDTA). The UBI® SARS-CoV-2 ELISA is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The UBI® SARS-CoV-2 ELISA should not be used to diagnose or exclude acute SARS-CoV-2 infection. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, that meet requirements to perform high complexity testing. Results are for the detection of IgG SARS CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. Individuals may have detectable virus present for several weeks following seroconversion. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities. The sensitivity of the UBI® SARS-CoV-2 ELISA early after infection is unknown. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, direct testing for SARS-CoV-2 is necessary.
    [Show full text]
  • Molecular Diagnostic Assay Validation Update to the 2009 AMP Molecular Diagnostic Assay Validation White Paper
    Molecular Diagnostic Assay Validation Update to the 2009 AMP Molecular Diagnostic Assay Validation White Paper Members of the 2013 and 2014 Clinical Practice Committees of the Association for Molecular Pathology The 2013 AMP Clinical Practice Committee consisted of Matthew J. Bankowski, Milena Cankovic, Jennifer Dunlap, Larissa V. Furtado*, Jerald Gong, Thomas Huard, Linda Jeng*, Loren Joseph (Chair), Annette Kim, Bryan Krock, Marilyn M. Li, Mary Lowery-Nordberg, Melissa Miller, Caroline Sue Richards, and Paul Rothberg. *Project leads Standard of practice is not defined by this article, and there may be alternatives. See Disclaimer for further details. INTRODUCTION The goal of method validation in the molecular diagnostics laboratory is to ensure that a given test is ready for implementation in the clinical laboratory. To reach that goal, each step of the testing process must be carefully evaluated and documented. Such validation is relatively standardized for high volume automated assays in fields such as clinical chemistry. It is challenging to apply those standardized practices to molecular diagnostics laboratories, which rely heavily on low-volume labor-intensive tests, both FDA approved and laboratory- developed. Excellent and comprehensive documents have recently been published on this topic 1-10. This overview is intended to provide a brief practical reference that can be used to guide the validation process in molecular diagnostics laboratories. In addition, a sample summary checklist is provided in the appendix as a template to facilitate documentation of laboratory director review and sign off on the validation process when new assays are developed or adopted. SUMMARY CLIA (42 CFR 493.1253) and CAP (MOL 30785-31705) require that laboratories validate the performance of tests before reporting patient results.
    [Show full text]
  • Assay Qualification Recall…
    Assay Qualification Recall… Assay Qualification: • ACCURACY: Orthogonal method • PRECISION: Reproducibility: same day replicates, day to day, different operators • ROBUSTNESS: sensitivity to assay parameters • SPECIFICITY: sensitivity to matrix effects • DYNAMIC RANGE AND RESPONSE FUNCTION: Instrument benchmarking. +/- controls. Calibration curve. Limit of detection Goal Establish confidence in genomic assays used to identify on-target and off- target genome editing genomic locations and sequence variants. Simplified Genome Editing Process Design & Execute Source sample Screen for genome disruption Target Editing molecule Targeted Confirm sequence change Editing molecule sequence (e.g. T7 Endonuclease, Surveyor, HRMA, TIDE) Targeted (sequencing, qPCR) Editing molecule formulation Genome Wide Whole exome sequencing Delivery (e.g. GUIDE-Seq, Digenome-Seq, Whole genome sequencing CIRCLE-Seq, SITE-Seq, BLESS/BLISS) Assay Reference qualification Materials Activities and outputs: 1. Qualify genomic assays used to identify on-target and off-target genome editing genomic locations and sequence variants. 2. Develop & qualify reference materials – designed to mimic genome edited DNA complexity for use in benchmarking sequence verification assay limits of detection and sensitivity. Assay Qualification Process Assess assay precision (initially within NIST laboratories) Assess sources of variability and improve assay protocols and robustness (DoE) (NIST) Identify assay(s) of primary importance (community consensus) Refined assay protocols will be evaluated
    [Show full text]
  • A Polyacrylamide Gel Electrophoresis (PAGE) Method for Assay of Phytic Acid Species
    INTERNATIONAL ZINC NUTRITION CONSULTATIVE GROUP WWW.IZiNCG.ORG IZiNCG practical tips A Polyacrylamide Gel Electrophoresis (PAGE) Method for Assay of Phytic Acid Species The PAGE method illustrated here was first was described in Losito et al. (2009). The basic principle of chromatography is that different compounds will migrate at different rates down the gel and thus be separated. A video demonstration can be found at http://www.jove.com/details.php?id=3027, as described in Loss et al. (2011). As described in the video, this method was initially developed for the isolation and identification of compounds related to phytic acid called “inositol pyrophosphates”. These compounds have seven or eight phosphate esters per molecule, as compared with phytic acid (inositol hexaphosphate or IP6), which has six phosphate esters per molecule. PAGE is typically used to chromatographically separate and detect molecules of much higher molecular weight than inositol phosphates, such as proteins and nucleic acid fragments. To provide a gel of sufficient density to retain these lower molecular weight inositol phosphates, this method uses a much higher concentration of 33.3% acrylamide. 1. Required Reagents The following chemicals are widely available from many commercial sources. 1. 40% Acrylamide/Bisacrylamide (19:1) 2. Ammonium Persulfate (APS) 3. Tetramethylethylenediamine (TEMED) 4. Tris(hydroxymethyl)aminomethane (TRIS) Base 5. Boric Acid 6. Ethylenediaminetetraacetic acid (EDTA) 7. Toluidine Blue 8. Sodium Hydroxide 9. Orange G 2. Experimental Standards Standards are readily available from many commercial sources. 1. 1.0 mM IP6 prepared using phytic acid dodecasodium salt hydrate prepared from rice (Sigma, St. Louis MO, USA).
    [Show full text]
  • Sample and Assay Technologies
    QIAGEN – Sample and Assay Technologies Cheuvreux 7th German Corporate Conference Frankfurt, January 21, 2008 Dr. Joachim Schorr Senior Vice President Global Research & Development -1- Sample & Assay Technologies Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics, applied testing markets and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations for certain events including funding, budgets, and others), difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, the management of intellectual property, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with or furnished to the U.S.
    [Show full text]
  • Analytic Validation of Immunohistochemical Assays: a Comparison of Laboratory Practices Before and After Introduction of an Evidence-Based Guideline
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Arch Pathol Manuscript Author Lab Med. Author Manuscript Author manuscript; available in PMC 2019 December 31. Published in final edited form as: Arch Pathol Lab Med. 2017 September ; 141(9): 1247–1254. doi:10.5858/arpa.2016-0558-CP. Analytic Validation of Immunohistochemical Assays: A Comparison of Laboratory Practices Before and After Introduction of an Evidence-Based Guideline Patrick L. Fitzgibbons, MD, Jeffrey D. Goldsmith, MD, Rhona J. Souers, MS, Lisa A. Fatheree, BS, SCT(ASCP), Keith E. Volmar, MD, Lauren N. Stuart, MD, MBA, Jan A. Nowak, MD, PhD, J. Rex Astles, PhD, Raouf E. Nakhleh, MD Department of Pathology, St Jude Medical Center, Fullerton, California (Dr Fitzgibbons); the Department of Pathology, Boston Children’s Hospital, Boston, Massachusetts (Dr Goldsmith); the Biostatistics Department (Ms Souers) and the Pathology and Laboratory Quality Center (Ms Fatheree), College of American Pathologists, Northfield, Illinois; the Department of Pathology, UNC REX Healthcare, Raleigh, North Carolina (Dr Volmar); the Department of Pathology, Treasure Coast Pathology, East Ocean, Florida (Dr Stuart); the Department of Pathology, Roswell Park Cancer Institute, Buffalo, New York (Dr Nowak); the Office of Laboratory Systems Development, Division of Laboratory Systems, US Centers for Disease Control & Prevention, Atlanta, Georgia (Dr Astles); and the Department of Pathology, Mayo Clinic Jacksonville, Jacksonville, Florida (Dr Nakhleh). Abstract Context.——Laboratories must demonstrate analytic validity before any test can be used clinically, but studies have shown inconsistent practices in immunohistochemical assay validation. Objective.——To assess changes in immunohistochemistry analytic validation practices after publication of an evidence-based laboratory practice guideline.
    [Show full text]
  • ELISA) for Detection of Renibacterium Salmoninarum Antigen in Fish Tissue
    CHAPTER 6 Enzyme Linked Immunosorbent Assay (ELISA) for Detection of Renibacterium salmoninarum Antigen in Fish Tissue Kimberly True USFWS – California/Nevada Fish Health Center Anderson, California NWFHS Laboratory Procedures Manual - Second Edition, June 2004 Chapter 6 - Page 1 Chapter 6 - Table of Contents I. INTRODUCTION ........................................................................................................ 6-4 A. Standardization of Reagents 1. Standardization of Antibody Reagents 2. Optimization of Antibody Dilutions B. Tissue Collection and Processing C. Performing the Assay D. Interpretation of Data E. Quality Control II. ELISA - Day 1 Preparation ........................................................................................ 6-6 A. Coating Immunoplates with Antibody B. Preparing Wash Solution and Washer Reservoirs C. Thaw and Centrifuge Test Samples III. ELISA - Day 2 Running the Assay ............................................................................ 6-9 A. Washing Plates 1. Initial Priming of Washer 2. Wash Protocol B. Loading Tissue Samples and Controls C. Washing unbound antigen D. Adding Secondary HRP-labeled Conjugate E. Washing unbound antibody F. ABTS Substrate - Color Development G. Stop Solution and Plate Reading H. Equipment Maintenance upon completion of assay IV. INTERPRETATION OF DATA ............................................................................... 6-16 A. Quality Control B. Negative-Positive Determination V. BIBLIOGRAPHY ........................................................................................................
    [Show full text]
  • CELL CULTURE BASICS Handbook
    CELL CULTURE BASICS Cell Culture Basics Culture Cell www.invitrogen.com/cellculturebasics Handbook B-087243 0110 Contents Introduction . .1 Purpose of the Handbook . 1. Introduction to Cell Culture . 2. What is Cell Culture? . 2 Finite vs Continuous Cell Line . .2 Culture Conditions . .2 Cryopreservation . .2 Morphology of Cells in Culture . 3 Applications of Cell Culture . .3 Cell Culture Laboratory . .4 Safety . 4. Biosafety Levels . 4 SDS . 5 Safety Equipment . 5 Personal Protective Equipment (PPE) . 5 Safe Laboratory Practices . .5 Cell Culture Equipment . 6. Basic Equipment . 6 Expanded Equipment . .6 Additional Supplies . .6 Cell Culture Laboratory . 7. Aseptic Work Area . 7 Cell Culture Hood . .7 Cell Culture Hood Layout . .8 Incubator . 9 Storage . 9 Cryogenic Storage . .10 Cell Counter . .10 Cell Culture Basics | i Contents Aseptic Technique . .11 Introduction . .11 Sterile Work Area . .11 Good Personal Hygiene . .11 Sterile Reagents and Media . .12 Sterile Handling . .12 Aseptic Technique Checklist . .13 Biological Contamination . .14 Introduction . .14 Bacteria . .14 Yeasts . .15 Molds . .15 Viruses . .16 Mycoplasma . 16 Cross-Contamination . .17 Using Antibiotics . .17 Cell Culture Basics . .18 Cell Lines . .18 Selecting the Appropriate Cell Line . .18 Acquiring Cell Lines . 18 Culture Environment . .19 Adherent vs Suspension Culture . .19 Media . .20 pH . .21 CO2 . .21 Temperature . .21 Cell Morphology . .22 Mammalian Cells . .22 Variations in Mammalian Cell Morphology . .22 Morphology of 293 Cells . .23 Insect Cells . .24 Morphology of Sf21 Cells . .24 Morphology of Sf9 Cells . .25 ii | Cell Culture Basics Contents Methods . .26 Guidelines for Maintaining Cultured Cells . .26 What is Subculture? . .26 When to Subculture? . .27 Media Recommendations for Common Cell Lines .
    [Show full text]
  • Characterization of Critical Reagents for Ligand Binding Assays
    Characterization of Critical Reagents for Ligand Binding Assays 03_app_fly_Application Text Placeholder Ligand binding assays are utilized throughout the large molecule drug development process. However their robustness, accuracy and reproducibility depend on the quality of critical reagents. The unique characteristics of these reagents are crucial to assay performance, and require careful characterization. To ensure their consistent characterization in bioanalytical laboratories, a team of pharmaceutical scientists have outlined recommendations and best practices for this process, particularly during the early stages of drug development. Drug development relies on ligand binding assays (LBAs), This article summarizes the guidelines for characterizing which are bioanalytical procedures widely used to measure critical reagents, particularly during the early stages of drug the immunogenicity of biotherapeutic molecules, and development. In this context, characterization refers to the determine drug concentrations for pharmacokinetic analyses. process of identifying the physicochemical attributes of The accuracy and performance of LBAs, however, depends on these reagents (O’Hara et al. 2012). In addition, examples are the quality of key reagents, called critical reagents. The Global shown to provide insight into the analytic methods applied Bioanalysis Consortium (GBC) and the European Medicines at Bio-Rad for quality control and analytical antibody batch Agency classify critical reagents as analyte specific or binding characterization as
    [Show full text]